Among the various anti-cancer treatments, dynamic phototherapy (PDT) is based on the irradiation by visible light of a molecule (photosensitizer) allowing the production of singlet oxygen highly toxic to cells. Unfortunately, this technique has limitations since it is not targeted and is ineffective in hypoxic areas.
The project focuses on an innovative approach to targeted dynamic phototherapy (PDT) with a dual therapeutic action and which can work even in hypoxic environments. Our strategy is based on the outstanding properties of a photosensitive derivative to exceed the current limits of specificity and sensitivity of the PDT. To improve the selectivity of our compound, it includes a “ligand” residue that allows it to accumulate specifically at the tumor by targeting overexpressed proteins in the tumor tissue.
-New family of compounds in the PDT therapeutic arsenal
-Active molecule even in hypoxic conditions
-Tumour specific targeting
-Can be used with all PDT lighting systems conventionally used (medical devices and wavelength)
In vivo tests are underway to optimize the process; the demonstrator will be validated in the context of ovarian cancers.
This technique improves the management of solid cancers in addition to tumor resection surgery.